Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarMMa-9: Idecabtagene Vicleucel vs Lenalidomide Maintenance After ASCT in Newly Diagnosed Multiple Myeloma With Suboptimal Response
jRCT2061230084Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 3, randomised, open-label trial of idecabtagene vicleucel in multiple myeloma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival. Started May 2024; status: completed.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2061230084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230084.